New cocktail of drugs aims to tackle returning myeloma
NCT ID NCT07479979
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests a combination of four drugs—selinexor, carfilzomib, isatuximab, and dexamethasone—in people whose multiple myeloma has come back or stopped responding to treatment. The trial has two parts: first, a small safety run-in to find the right dose, then a larger group to see how well the combo works. About 62 participants will be enrolled, and the main goals are to check for side effects and measure how long the cancer stays under control.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- selinexor (oral drug), carfilzomib (IV drug), isatuximab (injected drug), and dexamethasone (steroid)
- What this could lead to
- If successful, this combination could offer a new treatment option for patients with multiple myeloma that has returned or stopped responding to prior therapy.
- What could go wrong
- This is an early-phase trial (Phase 1/2) with a small number of participants, so the combination may prove too toxic or not effective enough. Side effects from the drugs can be serious.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for REFRACTORY MULTIPLE MYELOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
University of Wisconsin
RECRUITINGMadison, Wisconsin, 53705, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Engineered donor cells could outsmart relapsed myeloma
- Can a Triple-Drug cocktail tame resistant myeloma?
- Can a One-Two drug punch beat back Hard-to-Treat myeloma?
- CAR-T breakthroughs come with infection risks – new study aims to decode them
- Double-barreled CAR t therapy takes aim at hard-to-treat myeloma
- Can a drug stop dangerous side effects of new myeloma therapies?